Empacoza 25 Mg 30 Tablets

Empacoza 25 Mg 30 Tablets

Description:

Empacoza 25 mg 30 tablets is a prescription oral antidiabetic medicine containing empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor. It is used as part of a comprehensive diabetes management plan, together with diet and exercise, to help lower high blood sugar levels in adults with type 2 diabetes mellitus. Empacoza can be used alone or in combination with other antidiabetic medicines and also helps reduce the risk of cardiovascular death in adults with type 2 diabetes who have established cardiovascular disease. It is not indicated for type 1 diabetes or diabetic ketoacidosis and is not recommended for children and adolescents under 18 years.

Indications:

• Type 2 diabetes mellitus in adults, as an adjunct to diet and exercise to improve glycemic control.
• Can be used as monotherapy in patients intolerant to metformin or when metformin is contraindicated.
• Can be used in combination with other antidiabetic agents (such as metformin, sulfonylureas, insulin, DPP-4 inhibitors, etc.) when additional blood sugar control is needed.
• Reduction of the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease.
• Helps reduce elevated fasting and postprandial blood glucose levels and supports long-term glycemic control (HbA1c reduction).

Active Ingredients / Key Components:

• Empagliflozin – 25 mg per film-coated tablet.
• Excipients: film-coating and tablet core excipients (full excipient list is not available in the provided information).

Dosage & Administration / How to Use:

• Usual adult dose: 25 mg (one tablet) once daily, or as directed by your physician. Some patients may start at a lower dose (such as 10 mg) depending on renal function and concomitant therapy; follow your doctor’s instructions.
• Route of administration: Oral use.
• Empacoza tablets can be taken with or without food. Swallow the tablet whole with a glass of water; do not crush or chew.
• Take the dose at the same time each day to maintain consistent blood levels and optimal blood sugar control.
• If you miss a dose and it is close to the time of your next dose, skip the missed dose and continue with your regular schedule. Do not take a double dose to make up for a forgotten tablet.
• Your doctor may adjust the dose based on blood sugar response, kidney function, and concomitant antidiabetic medications to minimize the risk of hypoglycemia.
• Always use Empacoza as part of a full diabetes management plan including diet, exercise, weight management, and regular blood glucose monitoring.

Clinical Benefits:

• Helps lower high blood sugar in adults with type 2 diabetes by increasing urinary glucose excretion through SGLT2 inhibition in the kidneys.
• Supports improved long-term glycemic control (HbA1c reduction), helping to reduce the risk of diabetes-related complications when used as prescribed.
• Contributes to modest weight reduction and a decrease in blood pressure in many patients due to its mechanism of action (osmotic diuresis and caloric loss).
• Reduces the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, when used as part of standard care.
• Can be combined with other antidiabetic medications to achieve better blood sugar control when monotherapy is insufficient.

Warnings & Contraindications:

• Do not use Empacoza if you are allergic (hypersensitive) to empagliflozin or any of the excipients in the product.
• Contraindicated in patients with type 1 diabetes mellitus.
• Contraindicated in patients with diabetic ketoacidosis (DKA), characterized by high blood sugar, increased ketones in blood or urine, nausea, vomiting, abdominal pain, difficulty breathing, confusion, or unusual fatigue.
• Do not take this medicine if you have severe kidney problems or are on dialysis. Dose adjustment or discontinuation may be required in moderate renal impairment; use only under close medical supervision.
• Not recommended for children and adolescents under 18 years of age due to insufficient safety and efficacy data.
• Should not be used during pregnancy or breast-feeding. If you become pregnant or plan to become pregnant, inform your doctor immediately to switch to a more suitable therapy.
• Use with caution in elderly patients, patients with low blood pressure, dehydration, or those taking diuretics, as empagliflozin may increase the risk of volume depletion and hypotension.
• Use with caution in patients with a history of genital infections, urinary tract infections, or conditions that predispose to infections, as SGLT2 inhibitors can increase the risk of genital and urinary tract infections.
• There is a risk of diabetic ketoacidosis even with moderately increased blood glucose; seek medical attention if you develop symptoms such as nausea, vomiting, abdominal pain, excessive thirst, difficulty breathing, confusion, or unusual fatigue.
• Consult your doctor before use if you have liver disease, recurrent urinary tract infections, cardiovascular disease, or are taking diuretics, antihypertensives, or other antidiabetic medications.
• Empacoza may increase the risk of hypoglycemia when used with insulin or insulin secretagogues (e.g., sulfonylureas); your doctor may reduce the dose of these agents.
• Consult your doctor before use if pregnant, nursing, taking medications, or have medical conditions such as kidney disease, liver disease, cardiovascular disease, or a history of ketoacidosis.
• Not intended to diagnose, treat, cure, or prevent any disease outside its approved indications.
• Keep out of reach of children.

Side Effects:

• Common side effects may include increased urination, thirst, mild dehydration, genital fungal infections (such as yeast infections), and urinary tract infections.
• Other possible side effects: dizziness or lightheadedness (especially when standing up), particularly in patients with low blood pressure or taking diuretics; mild increases in cholesterol levels; and skin itching or rash in some individuals.
• Serious side effects (seek immediate medical attention): signs of diabetic ketoacidosis (nausea, vomiting, abdominal pain, difficulty breathing, confusion, unusual fatigue), severe urinary tract infection (fever, chills, flank pain, burning on urination, blood in urine), severe genital infections, or signs of allergic reaction (swelling of face, lips, tongue or throat, severe rash, difficulty breathing).
• This is not a complete list of side effects. Inform your doctor or pharmacist if you notice any unusual or persistent symptoms while taking Empacoza.

Storage Instructions:

Store in a cool, dry place away from direct sunlight. Keep container tightly closed. Keep out of reach of children. Do not use after the expiry date printed on the pack. Store at or below the temperature indicated on the package insert (specific temperature range is not available in the provided information; follow the product label).

Specifications:

• Product type: Prescription antidiabetic medicine (SGLT2 inhibitor).
• Active ingredient strength: empagliflozin 25 mg per film-coated tablet.
• Form: Film-coated tablet for oral use.
• Pack size: 30 tablets per pack.
• Intended users: Adults with type 2 diabetes mellitus, as prescribed by a healthcare professional.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.